Brind.

The acquisition of Karuna Therapeutics by AbbVie was validated on August 20, 2025.

1 report, 1 independent Updated Aug 20

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Karuna Therapeutics AbbVie

Keep exploring

The entities involved

Karuna Therapeutics
biopharmaceutical company

Nothing else this week.
AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48

Coverage

Newest first; wire copies grouped

Aug 20ZacksDoes Cobenfy Have the Potential to Become a Top Drug for BMY? Bristol Myers BMY won FDA approval for xanomelineand trospiumchloride (formerly KarXT), an oral medication for the treatment of schizophr